Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)
benzoyl-L-tyrosyl-alanine · 1 trial · 2 indications
This breath test substrate is new and is hypothesized, based on preliminary studies, that it may be the answer to a much needed non-invasive pancreatic function test. At first stage, it will be compared to the current invasive gold standard: secretin induced ePFT.
| Arm | Type | Description |
|---|---|---|
| Di -petide breath tests and ePFT secretin induced | ACTIVE_COMPARATOR | Di peptide breath tests will be performed on subjects with known chronic pancreatitis |
| c13 di peptide breath tests | ACTIVE_COMPARATOR | Healthy volunteers to compare breath tests results to subjects with chronic pancreatitis |
| Name | Type | Description |
|---|---|---|
| benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala) | DRUG | 300 mg of powder form dissolved in one cup of tap water prior to breath test |
Inclusion Criteria: 1. Patients with chronic pancreatitis who meet at least one of the following criteria: * Adult men or women \>18 years of age. * Endoscopic retrograde cholangiopancreatography (ERCP), magnetic resonance cholangiopancreatography (MRCP), or endoscopic ultrasound demonstrati...
Benzoyl-L-tyrosyl-alanine is being studied for chronic pancreatitis, specifically as a diagnostic agent for detecting pancreatic exocrine insufficiency. It is a small molecule developed by Meridian Bioscience Inc and is in Phase 2 clinical development.
Benzoyl-L-tyrosyl-alanine is being developed by Meridian Bioscience Inc, which trades under the ticker VIVO. The company is responsible for its clinical development in chronic pancreatitis.
Benzoyl-L-tyrosyl-alanine is in Phase 2 clinical development. It is investigational and has not been approved by the FDA. One Phase 2 trial has been completed, and no active trials are currently listed.
Benzoyl-L-tyrosyl-alanine has been evaluated in one completed Phase 2 trial, NCT01259544, titled "BreathID Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency." The trial enrolled 33 participants with chronic pancreatitis or healthy volunteers in India.
Yes, benzoyl-L-tyrosyl-alanine is also known as benzoyl-L-tyrosyl-[1-13C]alanine, often abbreviated as Bz-Tyr-Ala. These names refer to the same investigational compound being developed by Meridian Bioscience Inc.